Home » Stocks » PTCT

PTC Therapeutics, Inc. (PTCT)

Stock Price: $58.41 USD -1.73 (-2.88%)
Updated Mar 8, 2021 4:00 PM EST - Market closed
After-hours: $59.08 +0.67 (1.15%) Mar 8, 4:13 PM
Market Cap 4.23B
Revenue (ttm) 380.77M
Net Income (ttm) -438.16M
Shares Out 66.03M
EPS (ttm) -6.64
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day March 8
Last Price $58.41
Previous Close $60.14
Change ($) -1.73
Change (%) -2.88%
Day's Open 60.48
Day's Range 58.30 - 60.57
Day's Volume 444,466
52-Week Range 30.79 - 70.82

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
PRNewsWire - 1 week ago

SOUTH PLAINFIELD, N.J., Feb. 26, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT), today announced that the European Medicines Agency (EMA) Committee for Medicinal Products for Human...

Zacks Investment Research - 1 week ago

PTC Therapeutics (PTCT) delivered earnings and revenue surprises of -20.00% and 4.76%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the s...

PRNewsWire - 1 week ago

SOUTH PLAINFIELD, N.J., Feb. 25, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced financial results for the fourth quarter and full year ending December 31, 2020 and ...

PRNewsWire - 1 week ago

SOUTH PLAINFIELD, N.J., Feb. 24, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT), today announced the publication of results from the dose finding Part 1 of the pivotal FIREFISH stu...

Zacks Investment Research - 2 weeks ago

PTC Therapeutics (PTCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

PRNewsWire - 2 weeks ago

SOUTH PLAINFIELD, N.J., Feb. 17, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT), today announced the initiation of the second stage of the FITE19 clinical trial to assess PTC299 in...

PRNewsWire - 1 month ago

SOUTH PLAINFIELD, N.J., Feb. 4, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) will host a conference call today at 5:30 p.m. E.T. to review results from its clinical study 045 of ...

Seeking Alpha - 1 month ago

Risk~reward tradeoffs and net payoffs offered by this group are better than those of most S&P 500 Index stocks and of most other Market-Maker [MM] forecast securities. They also outdo the pros...

PRNewsWire - 1 month ago

SOUTH PLAINFIELD, N.J., Jan. 13, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on January 6, 2021 it approved non-statutory stock options to purchase an aggre...

PRNewsWire - 1 month ago

SOUTH PLAINFIELD, N.J., Jan. 11, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) will present an update on its R&D pipeline and commercial progress at the 39th Annual J.P. Morgan He...

PRNewsWire - 2 months ago

SOUTH PLAINFIELD, N.J., Dec. 18, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on December 15, 2020 it approved non-statutory stock options to purchase an agg...

PRNewsWire - 3 months ago

SOUTH PLAINFIELD, N.J., Dec. 4, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on December 2, 2020 it approved non-statutory stock options to purchase an aggre...

PRNewsWire - 3 months ago

SOUTH PLAINFIELD, N.J., Dec. 4, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that Translarna™ (ataluren) has been granted marketing approval in the Russian Federa...

PRNewsWire - 3 months ago

SOUTH PLAINFIELD, N.J., Nov. 19, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company overview at Evercore ISI 3rd Annual HealthCON...

Seeking Alpha - 4 months ago

PTC Therapeutics, Inc. (PTCT) CEO Stuart Peltz on Q3 2020 Results - Earnings Call Transcript

Zacks Investment Research - 4 months ago

PTC Therapeutics (PTCT) delivered earnings and revenue surprises of 6.36% and 11.46%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the s...

PRNewsWire - 4 months ago

SOUTH PLAINFIELD, N.J., Oct. 29, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced financial results for the third quarter ending September 30, 2020 and provided a cor...

Zacks Investment Research - 4 months ago

PTC Therapeutics (PTCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

PRNewsWire - 4 months ago

SOUTH PLAINFIELD, N.J., Oct. 21, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that Evrysdi™ (risdiplam) was approved in Brazil by the National Health Surveillance...

Seeking Alpha - 4 months ago

ClearPoint Neuro: Becoming The World's Pre-Eminent Neurosurgery Platform

PRNewsWire - 5 months ago

SOUTH PLAINFIELD, N.J., Sept. 28, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that two-year data from Part 1 of the FIREFISH study demonstrated that infants on E...

PRNewsWire - 5 months ago

SOUTH PLAINFIELD, N.J., Sept. 25, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on September 21, 2020 it approved non-statutory stock options to purchase an a...

Zacks Investment Research - 6 months ago

PTC Therapeutics (PTCT) gets first commercial milestone payment from Roche for first commercial sale of Evrysdi in the United States.

Zacks Investment Research - 6 months ago

PTC Therapeutics??? (PTCT) MAA for Evrysdi is accepted by the European Medicines Agency for the treatment of spinal muscular atrophy.

Investors Business Daily - 6 months ago

PTC Therapeutics hit a milestone in Europe for its drug to treat the rare genetic disease spinal muscular atrophy, triggering a payment from partner Roche and sending PTCT stock rising.

Seeking Alpha - 7 months ago

PTC Therapeutics Looks Like A Better Value After Recent Pullback

The Motley Fool - 7 months ago

Roche and PTC Therapeutics will challenge Novartis and Biogen with competitive pricing for Evrysdi.

Other stocks mentioned: RHHBY
PRNewsWire - 7 months ago

SOUTH PLAINFIELD, N.J., Aug. 7, 2020 /PRNewswire/ -- PTC Therapeutics, Inc.

Seeking Alpha - 7 months ago

PTC Therapeutics, Inc. (PTCT) CEO Stuart Peltz on Q2 2020 Results - Earnings Call Transcript

Zacks Investment Research - 7 months ago

PTC Therapeutics (PTCT) delivered earnings and revenue surprises of -105.43% and -5.24%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 7 months ago

PTC Therapeutics (PTCT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

PRNewsWire - 7 months ago

SOUTH PLAINFIELD, N.J., July 22, 2020 /PRNewswire/ -- PTC Therapeutics, Inc.

PRNewsWire - 7 months ago

SOUTH PLAINFIELD, N.J., July 20, 2020 /PRNewswire/ -- PTC Therapeutics, Inc.

PRNewsWire - 8 months ago

SOUTH PLAINFIELD, N.J., June 29, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medic...

GuruFocus - 8 months ago

Investors have either become overwhelmed by the number of companies entering the quest to address Covid-19 or are having difficulty separating the wheat from the chaff.

Zacks Investment Research - 8 months ago

PTC Therapeutics (PTCT) gets an FDA sanction to begin a phase II/III study on its DHODH inhibitor PTC299 as a potential treatment of COVID-19. The study will start in the United States shortly.

Zacks Investment Research - 8 months ago

PTC (PTCT) commences a phase II/III study to evaluate PTC299, a dihydroorotate dehydrogenase (DHODH) inhibitor, as a potential treatment for COVID-19.

PRNewsWire - 8 months ago

SOUTH PLAINFIELD, N.J., June 17, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT), today announced that the U.S. Food and Drug Administration has authorized the initiation of a Phase...

PRNewsWire - 8 months ago

SOUTH PLAINFIELD, N.J., June 12, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced two-year data from Part 1 of the SUNFISH trial in children and adults with type 2 or...

PRNewsWire - 9 months ago

SOUTH PLAINFIELD, N.J., May 27, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that, due to the public health impact of the novel coronavirus (COVID-19) outbreak an...

Investors Business Daily - 9 months ago

PTC Therapeutics shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 77 to 82. The post PTC Therapeutics Clears Key Benchmark, Hitting 80-Plus RS Rating...

PRNewsWire - 9 months ago

SOUTH PLAINFIELD, N.J., May 15, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on May 11, 2020 it approved non-statutory stock options to purchase an aggregate...

Seeking Alpha - 10 months ago

PTC Therapeutics, Inc. (PTCT) CEO Stuart Peltz on Q1 2020 Results - Earnings Call Transcript

Zacks Investment Research - 10 months ago

PTC Therapeutics (PTCT) delivered earnings and revenue surprises of -55.17% and -13.17%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the st...

InvestorPlace - 10 months ago

RBC Capital has peered into its crystal ball to reveal some of the market's most exciting biotech stocks. Here are seven that stand out.

Other stocks mentioned: ATRA, BHVN, CBAY, MRNS, SLDB, TBIO
Zacks Investment Research - 10 months ago

PTC Therapeutics (PTCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GuruFocus - 11 months ago

The U.S. Food and Drug Administration is scheduled to make decisions on five therapies in the second quarter, and the one that could make the biggest impact on the company and its shares belon...

Other stocks mentioned: BMY, GNFT, ICPT, MDGL, NVS, RHHBY
Investors Business Daily - 11 months ago

A growing number of Covid-19 cases could frustrate biotech companies' efforts to enroll patients in clinical studies, an analyst said Tuesday.

Other stocks mentioned: CRBP, GILD, GLPG, ICPT
Seeking Alpha - 1 year ago

PTC Therapeutics, Inc. (PTCT) CEO Stuart Peltz on Q4 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

PTC Therapeutics (PTCT) delivered earnings and revenue surprises of -116.98% and 8.68%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the ...

About PTCT

PTC Therapeutics, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for the treatment of rare disorders. The company offers Translarna (ataluren) and Emflaza (deflazacort) for the treatment of nonsense mutation Duchenne muscular dystrophy in ambulatory patients. It is developing Translarna, which is in Phase 2 clinical study for the treatment of nonsense mutation aniridia and nonsense mutation Dravet syndrome/CDKL5; and RG7916 and RO7034067 for the treatment of patients with spinal muscular a... [Read more...]

Industry
Biotechnology
IPO Date
Jun 20, 2013
CEO
Stuart Peltz
Employees
959
Stock Exchange
NASDAQ
Ticker Symbol
PTCT
Full Company Profile

Financial Performance

In 2020, PTCT's revenue was $380.77 million, an increase of 24.04% compared to the previous year's $306.98 million. Losses were -$438.16 million, 74.2% more than in 2019.

Financial Statements

Analyst Forecasts

According to 13 analysts, the average rating for PTCT stock is "Buy." The 12-month stock price forecast is 63.45, which is an increase of 8.63% from the latest price.

Price Target
$63.45
(8.63% upside)
Analyst Consensus: Buy